Proteome Sciences Full Year 2024 Earnings: UK£0.011 loss per share (vs UK£0.008 loss in FY 2023)

Simply Wall St

Proteome Sciences (LON:PRM) Full Year 2024 Results

Key Financial Results

  • Revenue: UK£4.89m (down 2.8% from FY 2023).
  • Net loss: UK£3.41m (loss widened by 39% from FY 2023).
  • UK£0.011 loss per share (further deteriorated from UK£0.008 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

AIM:PRM Earnings and Revenue History April 12th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Proteome Sciences shares are down 21% from a week ago.

Risk Analysis

It is worth noting though that we have found 5 warning signs for Proteome Sciences (3 are a bit concerning!) that you need to take into consideration.

Valuation is complex, but we're here to simplify it.

Discover if Proteome Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.